CCT020312

CCT020312 Suppliers list
Company Name: ShangHai Caerulum Pharma Discovery Co., Ltd.  
Tel: 18149758185 18149758185
Email: sales-cpd@caerulumpharma.com
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Shanghai Jizhi Biochemical Technology Co. Ltd.  
Tel: 021-4009004166/18616739031 18616739031
Email: 3007523370@qq.com
Company Name: Fan De(Beijing) Biotechnology Co., Ltd.  
Tel: 15911056312
Email: liming@bio-fount.com

CCT020312 manufacturers

  • CCT020312
  • CCT020312 pictures
  • $56.00
  • 2026-07-27
  • CAS:324759-76-4
  • Purity: 99.12%
  • Supply Ability: 10g
  • CCT020312
  • CCT020312 pictures
  • $56.00
  • 2026-07-27
  • CAS:324759-76-4
  • Purity: 99.12%
  • Supply Ability: 10g
CCT020312 Basic information
Product Name:CCT020312
Synonyms:CCT020312;2(1H)-Quinolinone, 6-bromo-3-[5-(4-bromophenyl)-1-[3-(diethylamino)-1-oxopropyl]-4,5-dihydro-1H-pyrazol-3-yl]-4-phenyl-;CCT-020312,CCT020312;EIF2AK3 Activator, CCT020312
CAS:324759-76-4
MF:C31H30Br2N4O2
MW:650.4
EINECS:
Product Categories:
Mol File:324759-76-4.mol
CCT020312 Structure
CCT020312 Chemical Properties
density 1.48±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO: soluble
form A solid
pka9.43±0.70(Predicted)
color Light yellow to yellow
SMILESO=C1C(C2=NN(C(CCN(CC)CC)=O)C(C3=CC=C(Br)C=C3)C2)=C(C4=CC=CC=C4)C5=CC(Br)=CC=C5N1
Safety Information
WGK Germany WGK 2
Storage Class11 - Combustible Solids
MSDS Information
CCT020312 Usage And Synthesis
UsesCCT020312 is a selective EIF2AK3/PERK activator. CCT020312 elicits EIF2A phosphorylation in cells.
Biological ActivityCCT020312 is a selective activator of EIF2AK3/PERK. It induces phosphorylation of EIF2A in cells.
in vitroCCT020312 treatment effectively inhibits cell proliferation (as measured at 96 hours) even if treatment is for 2 hours only with subsequent compound washout, indicating that CCT020312 is capable of eliciting durable rather than transient cytostasis.
in vivo

Treatment of 15-week-old wildtype mice with the PERK activator CCT020312 (1-5 mg/kg; i.p.; once daily for 3 days) leads to increased levels of phosphorylated PERK and NRF2 in brain homogenates[2].
P301S transgenic mice treated with CCT020312 (2 mg/kg; i.p.; once daily for 6 weeks) performes significantly better in Morris water maze[2].

Animal Model:9-week-old P301S tau transgenic mice[2]
Dosage:2 mg/kg
Administration:Intraperitoneal injection; once daily for 6 weeks
Result:P301S transgenic mice treated with CCT020312 performed significantly better in Morris water maze.
target

EIF2AK3/PERK.

References[1] Stockwell SR, et al.Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling. PLoS One. 2012;7(1):e28568. DOI:10.1371/journal.pone.0028568
[2] Bruch J, et al. PERK activation mitigates tau pathology in vitro and in vivo. EMBO Mol Med. 2017 Mar;9(3):371-384. DOI:10.15252/emmm.201606664
CCT020312 Preparation Products And Raw materials
Tag:CCT020312(324759-76-4) Related Product Information
CCT020312 5-(4-BroMophenyl)-3-(1,2-dihydro-6-Methyl-2-oxo-4-phenyl-3-quinolinyl)-4,5-dihydro-γ-oxo-1H-Pyrazole-1-butanoic Acid CAY10760 DQP-26 4-oxo-4-[3-(2-oxo-4-phenyl-1,2-dihydroquinolin-3- yl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]butanoic acid (10α,24R)-9β-Methyl-19-norlanosta-5-ene-3β,11α,24,25-tetrol